

Supplementary Table 2. Clinical, functional, disease activity and serological parameters of male (n=249) and female (n=359) PsA patients during 24 months-follow up.

	T0	T6	T12	T24
TJ [0-68], mean (SD)				
Male	6.17 (5.23)	2.35 (3.60)	2.44 (4.28)	1.47 (3.57)
Female	9.30 (7.47)	4.64 (5.78)	3.16 (5.16)	1.69 (2.61)
<i>p</i>	<i>p</i> =0.03	<i>p</i> =0.05	<i>ns</i>	<i>ns</i>
SJ [0-66],mean (SD)				
Male	2.18 (2.45)	0.63 (1.25)	0.49 (1.74)	0.25 (0.78)
Female	2.29 (3.05)	0.96 (1.70)	0.70 (1.95)	0.26 (0.62)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
LEI [0-6]mean (SD)				
Male	2.34 (1.61)	0.54 (1.11)	0.23 (0.75)	0.19 (0.73)
Female	2.82 (1.95)	1.16 (1.64)	0.51 (1.08)	0.19 (0.49)
<i>p</i>	<i>ns</i>	<i>p</i> =0.05	<i>ns</i>	<i>ns</i>
Dactylitis [0-20] number digit, mean (SD)				
Male	0.23 (0.82)	0.06 (0.31)	0.02 (0.19)	0.01 (0.23)
Female	0.31 (1.51)	0.08 (0.55)	0.04 (0.32)	0.02 (0.14)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
PASI [0-72] mean (SD)				
Male	4.96 (7.29)	1.93 (4.28)	1.04 (2.52)	0.84 (4.10)
Female	3.70 (7.42)	1.50 (3.61)	0.64 (1.92)	0.55 (2.04)
<i>p</i>	<i>p</i> =0.05	<i>ns</i>	<i>ns</i>	<i>ns</i>
ESR [0-25](mm/h), mean (SD)				
Male	18.99 (18.67)	11.79 (10.33)	12.50 (12.75)	11.52 (11.06)
Female	22.59 (15.76)	18.73 (14.20)	16.72 (13.96)	17.64 (12.88)
<i>p</i>	<i>p</i> =0.04	<i>p</i> =0.04	<i>p</i> =0.05	<i>p</i> =0.05
CRP [0-6](mg/L), mean (SD)				
Male	7.54 (12.10)	4.17 (6.75)	3.40 (4.63)	3.17 (5.07)
Female	5.70 (7.79)	4.09 (5.89)	3.49 (5.29)	3.75 (5.61)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
DAPSA [0-164], mean (SD)				
Male	23.77 (11.73)	11.64 (8.02)	11.28 (9.88)	7.92 (8.16)
Female	26.35 (10.60)	16.01 (10.45)	12.83 (10.01)	7.51 (6.91)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
ASDAS [0-6], mean (SD)				
Male	3.04 (0.89)	1.94 (0.90)	1.74 (0.95)	1.60 (0.73)
Female	3.44 (3.76)	2.25 (1.13)	1.89 (1.08)	1.61 (0.65)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
HAQ-S [0-8], mean (SD)				
Male	1.09 (0.67)	0.75 (0.67)	0.60 (0.66)	0.47 (0.64)
Female	1.42 (0.91)	1.01 (0.68)	0.76 (0.73)	0.59 (0.64)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
VAS-pain [0-10], mean (SD)				
Male	6.50 (1.78)	3.82 (2.25)	3.09 (2.47)	2.55 (2.36)
Female	6.84 (1.56)	4.68 (2.24)	3.42 (2.54)	2.52 (2.30)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
VAS-gh [0-10], mean (SD)				
Male	6.56 (1.54)	3.76 (2.19)	3.02 (2.40)	2.49 (2.20)
Female	6.84 (4.44)	4.65 (2.21)	3.18 (2.49)	2.35 (2.40)

<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
BASDAI [0-10], mean (SD)				
Male	5.18 (2.17)	3.35 (2.09)	3.25 (2.21)	2.61 (1.87)
Female	5.25 (2.19)	3.65 (2.83)	3.43 (2.12)	2.59 (1.28)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>
BASFI [0-10], mean (SD)				
Male	5.16 (2.27)	3.49 (2.08)	2.75 (1.96)	2.51 (1.60)
Female	5.19 (2.05)	3.93 (1.95)	2.88 (1.80)	2.44 (1.02)
<i>p</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>	<i>ns</i>

Data are expressed as mean (SD). $p \leq 0.05$. Values were computed by means of a chi-square test (for proportion) or Wilcoxon's test (for continuous data).

Legend: TJ, Tender Joint; SJ, Swollen Joint; LEI, Leeds Enthesitis Index; PASI, Psoriasis Area Severity Index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; ASDAS, Ankylosing Spondylitis Disease Activity Score; HAQ: Health Assessment Questionnaire modified for spondyloarthritis; VAS pain, Visual Analogue Scale pain; VAS gh, Visual Analogue Scale global health; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index.